For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a serious condition, the introduction of Tafamidis and the formulated version represents a true breakthrough . These novel therapies protect the transthyretin protein, preventing its harmful build-up and lessening the imp